Antiviral Therapy and Long-term Outcome of Chronic Hepatitis B Patients in China (CATLOB study): a National Multicenter, Prospective, Observational Real-World Study (Shan Dong Province)

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100041835

Enrollment

Unknown

Registered

2021-01-07

Start date

2021-02-01

Completion date

Unknown

Last updated

2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

Treatment group:Treatment with Novaferon

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Chronic HBV infection (HBsAg positive for more than 6 months, or HBsAg positive for less than 6 months, but liver biopsy within 1 year is consistent with the pathological characteristics of chronic hepatitis B, and other liver diseases are excluded); 2. Age not less 18 years old; 3. The patient signed the informed consent

Exclusion criteria

Exclusion criteria: In order to reduce selection bias, exclusion criteria were not set, and relevant clinical practice data were recorded truthfully.

Design outcomes

Primary

Measure	Time frame
The occurrence rate of HCC;	—

Secondary

Measure	Time frame
HBsAg conversion ratio;HBsAg seroconversion ratio;Improvement ratio of fibrosis;Incidence of cirrhosis within 5 years;	—

Countries

China

Contacts

Public ContactXin Yongning

Qingdao Municipal Hospital

xinyongning@163.com+86 532-82789463

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026